Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

• Status: Unknown status
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching placebo. After receiving the initial therapy for eight weeks, the participants will cross over to the alternate therapy for an additional eight weeks. Each treatment period will be separated by a two-week period of daily placebo. The hypothesis is that treatment with valacyclovir will result in a significant reduction in serum levels of hepatitis C virus ribonucleic acid.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: G.V. (Sonny) Montgomery VA Medical Center
• Treatments: Acyclovir; Valacyclovir

Criteria

Inclusion Criteria:

• Clinical diagnosis of hepatitis C infection

• Clinical diagnosis of herpes simplex type 2 infection

Exclusion Criteria:

• HIV infection

• Other forms of chronic liver disease

• Chronic medical conditions

• On immunosuppressive medications